{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:23:28Z","timestamp":1790346208856,"version":"4.1.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11154-025-09978-1","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:20:06Z","timestamp":1749608406000},"page":"901-915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review"],"prefix":"10.1007","volume":"26","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Caldarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Antonio","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Mattogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauretti","family":"Liverana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Calandrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tartaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Doglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"9978_CR1","doi-asserted-by":"publisher","unstructured":"Melmed S et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022;43(6):1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010","DOI":"10.1210\/endrev\/bnac010"},{"key":"9978_CR2","doi-asserted-by":"publisher","unstructured":"Bashari WA, Gillett D, MacFarlane J, Scoffings D, Gurnell M, Pituitary Imaging,. Pituit. Jan. 2022;677\u2013721. https:\/\/doi.org\/10.1016\/B978-0-323-99899-4.00022-6.","DOI":"10.1016\/B978-0-323-99899-4.00022-6"},{"key":"9978_CR3","doi-asserted-by":"publisher","unstructured":"Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas. JAMA. Apr. 2023;329(16):1386. https:\/\/doi.org\/10.1001\/jama.2023.5444.","DOI":"10.1001\/jama.2023.5444"},{"key":"9978_CR4","doi-asserted-by":"publisher","unstructured":"Petersenn S et al. Dec., Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol. 2023;19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","DOI":"10.1038\/s41574-023-00886-5"},{"key":"9978_CR5","doi-asserted-by":"publisher","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","DOI":"10.1016\/S2213-8587(22)00244-3"},{"key":"9978_CR6","doi-asserted-by":"publisher","unstructured":"Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S. An individualized approach to the management of Cushing disease. Nat Rev Endocrinol. 2023;19(10):581\u2013599. https:\/\/doi.org\/10.1038\/s41574-023-00868-7","DOI":"10.1038\/s41574-023-00868-7"},{"key":"9978_CR7","doi-asserted-by":"publisher","unstructured":"Fleseriu M et al. Dec., Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"9978_CR8","doi-asserted-by":"publisher","unstructured":"MacFarlane J et al. Advances in the Imaging of Pituitary Tumors. 2020. W.B. Saunders. https:\/\/doi.org\/10.1016\/j.ecl.2020.06.002","DOI":"10.1016\/j.ecl.2020.06.002"},{"key":"9978_CR9","doi-asserted-by":"publisher","unstructured":"Bashari WA et al. Modern imaging of pituitary adenomas. Apr 01 2019 Bailliere Tindall Ltd https:\/\/doi.org\/10.1016\/j.beem.2019.05.002","DOI":"10.1016\/j.beem.2019.05.002"},{"key":"9978_CR10","doi-asserted-by":"publisher","unstructured":"Bi WL, Laws ER. Metabolic imaging in the detection of growth hormone-secreting pituitary adenomas. World Neurosurg. Sep. 2014;82(3):329\u201330. https:\/\/doi.org\/10.1016\/j.wneu.2014.03.014.","DOI":"10.1016\/j.wneu.2014.03.014"},{"key":"9978_CR11","doi-asserted-by":"publisher","unstructured":"Page MJ et al. Mar., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"9978_CR12","doi-asserted-by":"publisher","unstructured":"Ikeda H, Ohhashi G. Demonstration of high coincidence of pituitary adenoma in patients with ruptured Rathke\u2019s cleft cyst: Results of a prospective study. Clin Neurol Neurosurg. 2015;139:144\u2013151. https:\/\/doi.org\/10.1016\/j.clineuro.2015.09.018","DOI":"10.1016\/j.clineuro.2015.09.018"},{"key":"9978_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101513","author":"R Senanayake","year":"2021","unstructured":"Senanayake R, et al. New types of localization methods for adrenocorticotropic hormone-dependent cushing\u2019s syndrome. Jan 01. 2021. https:\/\/doi.org\/10.1016\/j.beem.2021.101513. Bailliere Tindall Ltd.","journal-title":"Jan 01"},{"key":"9978_CR14","doi-asserted-by":"publisher","unstructured":"Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M. Clinical usefulness of coregistered 11\u00a0C-methionine positron emission tomography\/3-T magnetic resonance imaging at the follow-up of acromegaly. 2014. Elsevier Inc. https:\/\/doi.org\/10.1016\/j.wneu.2013.11.011","DOI":"10.1016\/j.wneu.2013.11.011"},{"key":"9978_CR15","doi-asserted-by":"publisher","unstructured":"Haberbosch L et al. Feb., Dual Role for l-[Methyl-11\u00a0C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence. J Nucl Med. 2024;65(2):327\u2013328. https:\/\/doi.org\/10.2967\/jnumed.123.266446","DOI":"10.2967\/jnumed.123.266446"},{"key":"9978_CR16","doi-asserted-by":"publisher","unstructured":"Gillett D, et al. Development of a bespoke Phantom to optimize molecular PET imaging of pituitary tumors. EJNMMI Phys. Dec. 2023;10(1). https:\/\/doi.org\/10.1186\/s40658-023-00552-9.","DOI":"10.1186\/s40658-023-00552-9"},{"key":"9978_CR17","doi-asserted-by":"publisher","unstructured":"Bendor-Samuel OM, Pal A, Cudlip S, Anderson G, Salgia S, Makaya T. Pituitary gigantism: A rare learning opportunity. Arch Dis Child Educ Pract Ed. 2020;105(2):111\u2013116. https:\/\/doi.org\/10.1136\/archdischild-2018-316282","DOI":"10.1136\/archdischild-2018-316282"},{"key":"9978_CR18","doi-asserted-by":"publisher","unstructured":"Haberbosch L et al. Mar., Real-world experience with 11\u00a0C-methionine positron emission tomography in the management of acromegaly. Eur J Endocrinol. 2024;190(4):307\u2013313. https:\/\/doi.org\/10.1093\/ejendo\/lvae028","DOI":"10.1093\/ejendo\/lvae028"},{"key":"9978_CR19","doi-asserted-by":"publisher","unstructured":"Bashari WA et al. Jun., PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus. 2020;48(6):E8. https:\/\/doi.org\/10.3171\/2020.3.FOCUS2052","DOI":"10.3171\/2020.3.FOCUS2052"},{"key":"9978_CR20","doi-asserted-by":"publisher","unstructured":"Zhang F, et al. The combination of 13\u00a0N-ammonia and 11\u00a0C-methionine in differentiation of residual\/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy. BMC Cancer. Dec. 2021;21(1). https:\/\/doi.org\/10.1186\/s12885-021-08574-1.","DOI":"10.1186\/s12885-021-08574-1"},{"key":"9978_CR21","unstructured":"Koulouri O et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following 1 localisation by 11\u00a0C-methionine PET-CT co-registered with MRI 2 3."},{"key":"9978_CR22","doi-asserted-by":"publisher","unstructured":"Kontogeorgos G, Thodou E. Double adenomas of the pituitary: an imaging, pathological, and clinical diagnostic challenge. 2019. Springer. https:\/\/doi.org\/10.1007\/s42000-019-00126-4","DOI":"10.1007\/s42000-019-00126-4"},{"key":"9978_CR23","doi-asserted-by":"publisher","unstructured":"Bashari WA et al. Jul., Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas. J Nucl Med. 2021;62:57S-62S. https:\/\/doi.org\/10.2967\/jnumed.120.251546","DOI":"10.2967\/jnumed.120.251546"},{"key":"9978_CR24","doi-asserted-by":"publisher","unstructured":"Taku N, Koulouri O, Scoffings D, Gurnell M, Burnet N. The use of 11 carbon methionine positron emission tomography (PET) imaging to enhance radiotherapy planning in the treatment of a giant, invasive pituitary adenoma. BJR|case Rep. Jun. 2017;3(2):20160098. https:\/\/doi.org\/10.1259\/bjrcr.20160098.","DOI":"10.1259\/bjrcr.20160098"},{"key":"9978_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3233\/CBM-130353","volume":"14","author":"G Kontogeorgos","year":"2014","unstructured":"Kontogeorgos G. New horizons in diagnosis and management of endocrine tumors. Cancer Biomarkers. 2014;14:2\u20133. https:\/\/doi.org\/10.3233\/CBM-130353.","journal-title":"Cancer Biomarkers"},{"key":"9978_CR26","doi-asserted-by":"publisher","unstructured":"Wang Z, et al. Clinical application of combination [11\u00a0C]C-methionine and [13\u00a0N]N-ammonia PET\/CT in recurrent functional pituitary adenomas with negative MRI or [18F]F-FDG PET\/CT. BMC Endocr Disord. Dec. 2024;24(1). https:\/\/doi.org\/10.1186\/s12902-024-01543-2.","DOI":"10.1186\/s12902-024-01543-2"},{"key":"9978_CR27","doi-asserted-by":"publisher","unstructured":"Quinn M, Bashari W, Smith D, Gurnell M, Agha A. A remarkable case of thyrotoxicosis initially caused by graves\u2019 disease followed by a probable TSHoma-a case report. BMC Endocr Disord. Aug. 2020;20(1). https:\/\/doi.org\/10.1186\/s12902-020-00611-7.","DOI":"10.1186\/s12902-020-00611-7"},{"key":"9978_CR28","doi-asserted-by":"publisher","unstructured":"Gillett D, et al. Localization of TSH-secreting pituitary adenoma using 11\u00a0C-methionine image subtraction. EJNMMI Res. 2022;12(1). https:\/\/doi.org\/10.1186\/s13550-022-00899-7.","DOI":"10.1186\/s13550-022-00899-7"},{"key":"9978_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30311-4","author":"O Koulouri","year":"2016","unstructured":"Koulouri O, et al. Localisation of an occult thyrotropinoma with 11\u00a0C-methionine PET-CT before and after somatostatin analogue therapy. Dec 01. 2016. https:\/\/doi.org\/10.1016\/S2213-8587(16)30311-4. Lancet Publishing Group.","journal-title":"Dec 01"},{"issue":"3","key":"9978_CR30","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1097\/RLU.0000000000001085","volume":"41","author":"Z Feng","year":"2016","unstructured":"Feng Z, et al. Utility of 11\u00a0C-methionine and 18F-FDG PET\/CT in patients with functioning pituitary adenomas. Clin Nucl Med. 2016;41(3):e130\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000001085.","journal-title":"Clin Nucl Med"},{"key":"9978_CR31","doi-asserted-by":"publisher","unstructured":"Bakker LEH et al. Aug., Implementation of functional imaging using 11\u00a0C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary. 2022;25(4):587\u2013601. https:\/\/doi.org\/10.1007\/s11102-022-01230-2","DOI":"10.1007\/s11102-022-01230-2"},{"key":"9978_CR32","doi-asserted-by":"publisher","unstructured":"Bashari WA, et al. 11\u00a0C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. Pituitary. Aug. 2022;25(4):573\u201386. https:\/\/doi.org\/10.1007\/s11102-022-01229-9.","DOI":"10.1007\/s11102-022-01229-9"},{"key":"9978_CR33","doi-asserted-by":"publisher","unstructured":"Sagan KP, Andrysiak-Mamos E, Sagan L, Nowacki P, Ma\u0142kowski B, Syrenicz A. Cushing\u2019s Syndrome in a Patient With Rathke\u2019s Cleft Cyst and ACTH Cell Hyperplasia Detected by 11\u00a0C-Methionine PET Imaging\u2014A Case Presentation. Front Endocrinol (Lausanne). Jul. 2020;11. https:\/\/doi.org\/10.3389\/fendo.2020.00460.","DOI":"10.3389\/fendo.2020.00460"},{"key":"9978_CR34","doi-asserted-by":"publisher","unstructured":"Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine-positron emission tomography\/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg. 2010;112(4):750\u2013755. https:\/\/doi.org\/10.3171\/2009.7.JNS09285","DOI":"10.3171\/2009.7.JNS09285"},{"key":"9978_CR35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf047","author":"RM Furnica","year":"2025","unstructured":"Furnica RM, et al. Diagnostic value of 11\u00a0C-Methionine PET-CT imaging in persistent or recurrent Cushing disease after surgery. J Clin Endocrinol Metab Jan. 2025. https:\/\/doi.org\/10.1210\/clinem\/dgaf047.","journal-title":"J Clin Endocrinol Metab Jan"},{"key":"9978_CR36","doi-asserted-by":"publisher","unstructured":"Lurquin F, et al. Ectopic sphenoidal ACTH-secreting adenoma revealed by 11\u00a0C Methionine PET scan: case report. BMC Endocr Disord. Dec. 2023;23(1). https:\/\/doi.org\/10.1186\/s12902-023-01298-2.","DOI":"10.1186\/s12902-023-01298-2"},{"key":"9978_CR37","doi-asserted-by":"publisher","unstructured":"Koulouri O et al. Oct., A role for 11\u00a0C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome, in European Journal of Endocrinology, BioScientifica Ltd., 2015, pp. M107\u2013M120. https:\/\/doi.org\/10.1530\/EJE-15-0616","DOI":"10.1530\/EJE-15-0616"},{"key":"9978_CR38","doi-asserted-by":"publisher","unstructured":"Berkmann S et al. Dec., Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI, Pituitary, vol. 24, no. 6, pp. 878\u2013886, 2021, https:\/\/doi.org\/10.1007\/s11102-021-01160-5","DOI":"10.1007\/s11102-021-01160-5"},{"key":"9978_CR39","doi-asserted-by":"publisher","unstructured":"Stanly A et al. Dec., Utility of F18-FDG PET\/CT in the Evaluation of Pituitary Uptake, World J Nucl Med, vol. 23, no. 04, pp. 234\u2013241, 2024, https:\/\/doi.org\/10.1055\/s-0044-1787967","DOI":"10.1055\/s-0044-1787967"},{"key":"9978_CR40","doi-asserted-by":"publisher","unstructured":"Wang H et al. Mar., PET\/MRI in the diagnosis of hormone-producing pituitary microadenoma: A prospective pilot study, Journal of Nuclear Medicine, vol. 59, no. 3, pp. 523\u2013528, 2018, https:\/\/doi.org\/10.2967\/jnumed.117.191916","DOI":"10.2967\/jnumed.117.191916"},{"key":"9978_CR41","doi-asserted-by":"publisher","unstructured":"Giustina A, Gola M, Doga M, Rosei EA. Primary Lymphoma of the Pituitary: An Emerging Clinical Entity, J Clin Endocrinol Metab, vol. 86, no. 10, pp. 4567\u20134575, Oct. 2001, https:\/\/doi.org\/10.1210\/jcem.86.10.7909","DOI":"10.1210\/jcem.86.10.7909"},{"key":"9978_CR42","doi-asserted-by":"publisher","unstructured":"Tsukamoto T, Miki Y. Imaging of pituitary tumors: an update with the 5th WHO Classifications\u2014part 1. Pituitary neuroendocrine tumor (PitNET)\/pituitary adenoma, Aug. 01, 2023, Springer. https:\/\/doi.org\/10.1007\/s11604-023-01400-7","DOI":"10.1007\/s11604-023-01400-7"},{"key":"9978_CR43","doi-asserted-by":"publisher","unstructured":"Ryu SI, Tafti BA, Skirboll SL. Pituitary Adenomas Can Appear as Hypermetabolic Lesions in 18 F-FDG PET Imaging, Journal of Neuroimaging, vol. 20, no. 4, pp. 393\u2013396, Oct. 2010, https:\/\/doi.org\/10.1111\/j.1552-6569.2008.00347.x","DOI":"10.1111\/j.1552-6569.2008.00347.x"},{"key":"9978_CR44","doi-asserted-by":"publisher","unstructured":"Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: Clinical significance and differential diagnostic criteria, Journal of Nuclear Medicine, vol. 52, no. 4, pp. 547\u2013550, Apr. 2011, https:\/\/doi.org\/10.2967\/jnumed.110.083733","DOI":"10.2967\/jnumed.110.083733"},{"key":"9978_CR45","doi-asserted-by":"publisher","unstructured":"Goulart CR, et al. Newly diagnosed Sellar tumors in patients with cancer: A diagnostic challenge and management dilemma. World Neurosurg. Oct. 2017;106:254\u201365. https:\/\/doi.org\/10.1016\/j.wneu.2017.06.139.","DOI":"10.1016\/j.wneu.2017.06.139"},{"key":"9978_CR46","doi-asserted-by":"publisher","unstructured":"Hoang JK et al. Jul., Management of Incidental Pituitary Findings on CT, MRI, and 18F-Fluorodeoxyglucose PET: A White Paper of the ACR Incidental Findings Committee, Journal of the American College of Radiology, vol. 15, no. 7, pp. 966\u2013972, 2018, https:\/\/doi.org\/10.1016\/j.jacr.2018.03.037","DOI":"10.1016\/j.jacr.2018.03.037"},{"key":"9978_CR47","doi-asserted-by":"publisher","unstructured":"Maffei P, et al. A very rare case of nonfunctioning pituitary adenoma incidentally disclosed at 18F-FDG PET\/CT. Clin Nucl Med. May 2012;37(5):e100\u20131. https:\/\/doi.org\/10.1097\/RLU.0b013e3182485217.","DOI":"10.1097\/RLU.0b013e3182485217"},{"key":"9978_CR48","doi-asserted-by":"publisher","unstructured":"Oldfield EH, Merrill MJ. Apoplexy of pituitary adenomas: The perfect storm, J Neurosurg, vol. 122, no. 6, pp. 1444\u20131449, Jun. 2015, https:\/\/doi.org\/10.3171\/2014.10.JNS141720","DOI":"10.3171\/2014.10.JNS141720"},{"key":"9978_CR49","doi-asserted-by":"publisher","unstructured":"Jeong SY et al. Dec., Incidental pituitary uptake on whole-body 18F-FDG PET\/CT: A multicentre study, Eur J Nucl Med Mol Imaging, vol. 37, no. 12, pp. 2334\u20132343, 2010, https:\/\/doi.org\/10.1007\/s00259-010-1571-5","DOI":"10.1007\/s00259-010-1571-5"},{"key":"9978_CR50","doi-asserted-by":"crossref","unstructured":"Gemmel F, Balink H, Collins J, Oomen P. Occult prolactinoma diagnosed by FDG PET\/CT, 2010. [Online]. Available: www.nuclearmed.com.","DOI":"10.1097\/RLU.0b013e3181d19098"},{"key":"9978_CR51","doi-asserted-by":"crossref","unstructured":"Skoura E, Datseris IE, Xekouki P, Tolis G, Stratakis CA. SPECT and 18 F-FDG PET\/CT imaging of multiple paragangliomas and a growth hormoneyproducing pituitary adenoma as phenotypes from a novel succinate dehydrogenase subunit D mutation, 2013. [Online]. Available: www.nuclearmed.com.","DOI":"10.1097\/RLU.0000000000000235"},{"issue":"4","key":"9978_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11102-009-0180-4","volume":"12","author":"AS Alzahrani","year":"2009","unstructured":"Alzahrani AS, Farhat R, Al-Arifi A, Al-Kahtani N, Kanaan I, Abouzied M. The diagnostic value of fused positron emission tomography\/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in cushing\u2019s disease. Pituitary. 2009;12(4):309\u201314. https:\/\/doi.org\/10.1007\/s11102-009-0180-4.","journal-title":"Pituitary"},{"key":"9978_CR53","doi-asserted-by":"publisher","unstructured":"Li X, et al. Case report and literature review: ectopic Thyrotropin-Secreting pituitary adenoma in the suprasellar region. Front Endocrinol (Lausanne). Mar. 2021;12. https:\/\/doi.org\/10.3389\/fendo.2021.619161.","DOI":"10.3389\/fendo.2021.619161"},{"key":"9978_CR54","doi-asserted-by":"publisher","unstructured":"Huang Y, Wen X, Liang X, Xu L. Mixed thyrotropin-secreting pituitary neuroendocrine tumor coexisting with Graves\u2019 disease: a case report, Front Med (Lausanne), vol. 11, Sep. 2024, https:\/\/doi.org\/10.3389\/fmed.2024.1436400","DOI":"10.3389\/fmed.2024.1436400"},{"key":"9978_CR55","doi-asserted-by":"publisher","unstructured":"Zhu C, et al. Central hyperthyroidism due to an ectopic TSH-secreting pituitary tumor: a case report and literature review. Front Endocrinol (Lausanne). 2024;15. https:\/\/doi.org\/10.3389\/fendo.2024.1301260.","DOI":"10.3389\/fendo.2024.1301260"},{"key":"9978_CR56","doi-asserted-by":"publisher","unstructured":"Kim S, et al. Ectopic Thyroid-Stimulating Hormone\u2013Secreting pituitary adenoma of the nasopharynx diagnosed by gallium 68 DOTATATE positron emission tomography\/computed tomography. World Neurosurg. May 2019;125:400\u20134. https:\/\/doi.org\/10.1016\/j.wneu.2019.02.022.","DOI":"10.1016\/j.wneu.2019.02.022"},{"key":"9978_CR57","doi-asserted-by":"publisher","unstructured":"Ishizaki U, Abe K, Takako K, Masui K, Sakai S, FDG PET\/CT Findings of Ectopic Pituitary Adenoma. Feb.,, Clin Nucl Med, vol. 45, no. 2, pp. 151\u2013153, 2020, https:\/\/doi.org\/10.1097\/RLU.0000000000002887","DOI":"10.1097\/RLU.0000000000002887"},{"key":"9978_CR58","doi-asserted-by":"publisher","unstructured":"Ding L, et al. Differentiation of suprasellar meningiomas from non-functioning pituitary macroadenomas by 18F-FDG and 13\u00a0N-Ammonia PET\/CT. BMC Cancer. Jun. 2020;20(1). https:\/\/doi.org\/10.1186\/s12885-020-06852-y.","DOI":"10.1186\/s12885-020-06852-y"},{"key":"9978_CR59","doi-asserted-by":"publisher","unstructured":"Beyhan E, Fenercio\u011flu \u00d6E, Karag\u00f6z Y, Erg\u00fcl N, \u00c7ermik TF. Mild68Ga PSMA-11 Uptake in Incidental Pituitary Adenoma, Mol Imaging Radionucl Ther, vol. 31, no. 3, pp. 244\u2013245, Oct. 2022, https:\/\/doi.org\/10.4274\/mirt.galenos.2021.97752","DOI":"10.4274\/mirt.galenos.2021.97752"},{"key":"9978_CR60","doi-asserted-by":"publisher","unstructured":"Lemelin A, et al. Pheochromocytoma, paragangliomas, and pituitary adenoma: an unusual association in a patient with an SDHD mutation. Case report. Medicine. Jul. 2019;98:e16594. https:\/\/doi.org\/10.1097\/MD.0000000000016594.","DOI":"10.1097\/MD.0000000000016594"},{"key":"9978_CR61","doi-asserted-by":"publisher","unstructured":"Chai A, Soon AYQ, Manish B, Tan JL. Ectopic sphenoid sinus pituitary adenoma masquerading as metastatic head and neck cancer. BMJ Case Rep. Mar. 2021;14(3). https:\/\/doi.org\/10.1136\/bcr-2020-240411.","DOI":"10.1136\/bcr-2020-240411"},{"issue":"4","key":"9978_CR62","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11102-009-0174-2","volume":"12","author":"M Andrioli","year":"2009","unstructured":"Andrioli M, Pecori Giraldi F, De Martin M, Cattaneo A, Carzaniga C, Cavagnini F. Differential diagnosis of ACTH-dependent hypercortisolism: imaging versus laboratory. Pituitary. 2009;12(4):294\u20136. https:\/\/doi.org\/10.1007\/s11102-009-0174-2.","journal-title":"Pituitary"},{"key":"9978_CR63","doi-asserted-by":"publisher","unstructured":"Sarkar S, Rajaratnam S, Chacko G, Mani S, Hesargatta AS, Chacko AG. Pure endoscopic transsphenoidal surgery for functional pituitary adenomas: outcomes with cushing\u2019s disease. Acta Neurochir (Wien). Jan. 2016;158(1):77\u201386. https:\/\/doi.org\/10.1007\/s00701-015-2638-7.","DOI":"10.1007\/s00701-015-2638-7"},{"key":"9978_CR64","doi-asserted-by":"publisher","unstructured":"Ammini A, et al. Etiology and clinical profile of patients with cushing\u2019s syndrome: A single center experience. Indian J Endocrinol Metab. Jan. 2014;18(1):99\u2013105. https:\/\/doi.org\/10.4103\/2230-8210.126586.","DOI":"10.4103\/2230-8210.126586"},{"key":"9978_CR65","doi-asserted-by":"publisher","unstructured":"Chittiboina P, Montgomery BK, Millo C, Herscovitch P, Lonser RR. High-resolution 18F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease, J Neurosurg, vol. 122, no. 4, pp. 791\u2013797, Apr. 2015, https:\/\/doi.org\/10.3171\/2014.10.JNS14911","DOI":"10.3171\/2014.10.JNS14911"},{"key":"9978_CR66","doi-asserted-by":"publisher","unstructured":"Kong Z, Wang Y, Ma W, Cheng X. FDG-PET\/CT in the detection of pituitary stalk ACTH-secreting adenoma, Jun. 01, 2020, Springer. https:\/\/doi.org\/10.1007\/s00259-019-04655-3","DOI":"10.1007\/s00259-019-04655-3"},{"key":"9978_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.12165","author":"HP Patt","year":"2014","unstructured":"Patt HP, Lele V, Lila A, Bandgar T, Shah N. Utility of hCRH-stimulated (18) F-FDG PET-CT scan in localisation of pituitary microadenoma in cushing\u2019s disease. Blackwell Publishing. 2014. https:\/\/doi.org\/10.1111\/1754-9485.12165.","journal-title":"Blackwell Publishing"},{"key":"9978_CR68","doi-asserted-by":"publisher","unstructured":"Boyle J et al. Jul., CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing\u2019s disease, Endocrine, vol. 65, no. 1, pp. 155\u2013165, 2019, https:\/\/doi.org\/10.1007\/s12020-019-01944-7","DOI":"10.1007\/s12020-019-01944-7"},{"key":"9978_CR69","doi-asserted-by":"publisher","unstructured":"Lu J, et al. Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1. Mol Cell Endocrinol. Jul. 2018;470:105\u201314. https:\/\/doi.org\/10.1016\/j.mce.2017.10.003.","DOI":"10.1016\/j.mce.2017.10.003"},{"key":"9978_CR70","doi-asserted-by":"publisher","unstructured":"Kim K, et al. Dexamethasone suppression for 18F-FDG PET\/CT to localize ACTH-secreting pituitary tumors. Cancer Imaging. Dec. 2023;23(1). https:\/\/doi.org\/10.1186\/s40644-023-00600-8.","DOI":"10.1186\/s40644-023-00600-8"},{"key":"9978_CR71","doi-asserted-by":"publisher","unstructured":"Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor, Pituitary, vol. 14, no. 4, pp. 418\u2013424, Dec. 2011, https:\/\/doi.org\/10.1007\/s11102-009-0211-1","DOI":"10.1007\/s11102-009-0211-1"},{"key":"9978_CR72","doi-asserted-by":"publisher","unstructured":"Hintz E, Tomlin J, Chengazi V, Vates G. Positron emission tomography-Computed tomography coregistration for diagnosis and intraoperative localization in recurrent Nelson syndrome. J Neurol Surg Rep. May 2013;74(01):033\u20136. https:\/\/doi.org\/10.1055\/s-0033-1346974.","DOI":"10.1055\/s-0033-1346974"},{"issue":"3","key":"9978_CR73","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12020-009-9247-2","volume":"36","author":"H Xu","year":"2009","unstructured":"Xu H, Zhang M, Zhai G, Zhang M, Ning G, Li B. The role of integrated 18F-FDG PET\/CT in identification of ectopic ACTH secretion tumors. Endocrine. 2009;36(3):385\u201391. https:\/\/doi.org\/10.1007\/s12020-009-9247-2.","journal-title":"Endocrine"},{"key":"9978_CR74","doi-asserted-by":"crossref","unstructured":"Hou Y, Zhu Z, Jin X, Wang R, Xing B. Combined 18 F-FDG PET\/CT and 99m Tc 3PRGD2 SPECT\/CT imaging in a case of pituitary metastases, 2013. [Online]. Available: www.nuclearmed.com.","DOI":"10.1097\/RLU.0b013e318292aa2f"},{"key":"9978_CR75","doi-asserted-by":"publisher","unstructured":"Cheung IHW, Mahboobani NR, Poon WL. Case report of large solitary skull base metastasis from renal cell carcinoma as initial clinical presentation: Radiological findings and differentials, Radiol Case Rep, vol. 19, no. 11, pp. 5376\u20135379, Nov. 2024, https:\/\/doi.org\/10.1016\/j.radcr.2024.07.169","DOI":"10.1016\/j.radcr.2024.07.169"},{"key":"9978_CR76","doi-asserted-by":"publisher","unstructured":"Ng S, et al. Pituitary metastasis of malignant melanoma misdiagnosed as pituitary adenoma: A case report and systematic review of the literature. Neurochirurgie. Nov. 2020;66(5):383\u201390. https:\/\/doi.org\/10.1016\/j.neuchi.2020.06.129.","DOI":"10.1016\/j.neuchi.2020.06.129"},{"key":"9978_CR77","doi-asserted-by":"publisher","unstructured":"Starc MT, Rosenblum MK, Meyers PA, Hatzoglou V. Rare presentation of ewing sarcoma metastasis to the Sella and suprasellar cistern. Clin Imaging. Jan. 2017;41:73\u20137. https:\/\/doi.org\/10.1016\/j.clinimag.2016.10.017.","DOI":"10.1016\/j.clinimag.2016.10.017"},{"key":"9978_CR78","doi-asserted-by":"publisher","unstructured":"Sahel O, Benameur Y, Nabih S, Biyi A, Doudouh A. A rare case of pituitary metastasis from breast cancer detected on fluorodeoxyglucose positron emission tomography\/computed tomography that presented as insipid diabetes, World J Nucl Med, vol. 20, no. 02, pp. 211\u2013214, Apr. 2021, https:\/\/doi.org\/10.4103\/wjnm.wjnm_88_20","DOI":"10.4103\/wjnm.wjnm_88_20"},{"key":"9978_CR79","doi-asserted-by":"publisher","unstructured":"Agarwal KK, Sharma P, Singla S, Suman S, Bal KCC, Kumar R. A rare case of Non\u2013Small cell lung Cancer metastasizing to the pituitary gland. Clin Nucl Med. May 2014;39(5):e318\u20139. https:\/\/doi.org\/10.1097\/RLU.0b013e31828da679.","DOI":"10.1097\/RLU.0b013e31828da679"},{"key":"9978_CR80","doi-asserted-by":"publisher","unstructured":"Lamorie-Foote K, et al. Melanoma metastasis to a nonfunctioning pituitary macroadenoma: illustrative case. J Neurosurgery: Case Lessons. Jun. 2021;1(23). https:\/\/doi.org\/10.3171\/CASE2167.","DOI":"10.3171\/CASE2167"},{"key":"9978_CR81","doi-asserted-by":"publisher","unstructured":"Donovan LE, Arnal AV, Wang SH, Odia Y. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy, CNS Oncol, vol. 5, no. 4, pp. 203\u2013209, Oct. 2016, https:\/\/doi.org\/10.2217\/cns-2016-0011","DOI":"10.2217\/cns-2016-0011"},{"issue":"4","key":"9978_CR82","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-09-0389","volume":"161","author":"C Hagen","year":"2009","unstructured":"Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631\u20137. https:\/\/doi.org\/10.1530\/EJE-09-0389.","journal-title":"Eur J Endocrinol"},{"key":"9978_CR83","doi-asserted-by":"publisher","unstructured":"Kamiya-Matsuoka C et al. Aug., Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma, Pituitary, vol. 19, no. 4, pp. 415\u2013421, 2016, https:\/\/doi.org\/10.1007\/s11102-016-0721-6","DOI":"10.1007\/s11102-016-0721-6"},{"key":"9978_CR84","doi-asserted-by":"publisher","unstructured":"Kwok MM, Virk JS, Michael M, McKinley M, Magarey MJR. Cervical Nodal Metastatic Pituitary Carcinoma: A Case Report, Ear Nose Throat J, vol. 101, no. 2, pp. 110\u2013113, Feb. 2022, https:\/\/doi.org\/10.1177\/0145561320944649","DOI":"10.1177\/0145561320944649"},{"key":"9978_CR85","doi-asserted-by":"publisher","unstructured":"Ortiz LD, et al. Anti-VEGF therapy in pituitary carcinoma. Pituitary. Sep. 2012;15(3):445\u20139. https:\/\/doi.org\/10.1007\/s11102-011-0346-8.","DOI":"10.1007\/s11102-011-0346-8"},{"key":"9978_CR86","doi-asserted-by":"publisher","unstructured":"Flores L, Karger AG et al. doi: https:\/\/doi.org\/10.1159\/000496019.","DOI":"10.1159\/000496019"},{"key":"9978_CR87","doi-asserted-by":"publisher","unstructured":"Joehlin-Price AS, Hardesty DA, Arnold CA, Kirschner LS, Prevedello DM, Lehman NL. Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and cushing\u2019s disease. Diagn Pathol. Apr. 2017;12(1). https:\/\/doi.org\/10.1186\/s13000-017-0624-5.","DOI":"10.1186\/s13000-017-0624-5"},{"key":"9978_CR88","doi-asserted-by":"publisher","unstructured":"Agarwal N, Kumar Verma S, Gopinathan VR, Sharma MC, Sharma A, Chandra SP. Prolactin secreting pituitary carcinoma and the role of peptide receptor radionuclide therapy: A brief report, 2024, https:\/\/doi.org\/10.4103\/neurol-india.Neurol","DOI":"10.4103\/neurol-india.Neurol"},{"key":"9978_CR89","doi-asserted-by":"crossref","unstructured":"Ju H, Zhou J, Pan Y, Lv J, Zhang Y. Evaluation of pituitary uptake incidentally identified on 18 F-FDG PET\/CT scan, 2017. [Online]. Available: www.impactjournals.com\/oncotarget\/","DOI":"10.18632\/oncotarget.15417"},{"key":"9978_CR90","doi-asserted-by":"publisher","unstructured":"Iglesias P, Cardona J, D\u00edez JJ, Elsevier BV. doi: https:\/\/doi.org\/10.1016\/j.ejim.2019.08.008.","DOI":"10.1016\/j.ejim.2019.08.008"},{"key":"9978_CR91","doi-asserted-by":"publisher","unstructured":"Mallereau CH, et al. Pituitary abscess: A challenging preoperative Diagnosis\u2014A multicenter study. Med (Lithuania). Mar. 2023;59(3). https:\/\/doi.org\/10.3390\/medicina59030565.","DOI":"10.3390\/medicina59030565"},{"key":"9978_CR92","doi-asserted-by":"publisher","unstructured":"Carbone RG, Penna D, Monselise A, Puppo F. Systemic sarcoidosis with pituitary adenoma, J Clin Imaging Sci, vol. 12, Jun. 2022, https:\/\/doi.org\/10.25259\/JCIS_43_2022","DOI":"10.25259\/JCIS_43_2022"},{"key":"9978_CR93","doi-asserted-by":"publisher","unstructured":"Duan L, et al. Primary pituitary lymphoma in immunocompetent patients: A report on two case studies and the review of literature. Front Endocrinol (Lausanne). Feb. 2021;11. https:\/\/doi.org\/10.3389\/fendo.2020.562850.","DOI":"10.3389\/fendo.2020.562850"},{"key":"9978_CR94","doi-asserted-by":"publisher","unstructured":"Morita K, et al. Pituitary lymphoma developing within pituitary adenoma. Int J Hematol. Jun. 2012;95(6):721\u20134. https:\/\/doi.org\/10.1007\/s12185-012-1075-0.","DOI":"10.1007\/s12185-012-1075-0"},{"key":"9978_CR95","doi-asserted-by":"publisher","unstructured":"Koga Y, Akai T, Shiro T, Kuroda S. Pituitary lymphoma appearing 9 years after pituitary adenoma resection, Surg Neurol Int, vol. 15, Jul. 2024, https:\/\/doi.org\/10.25259\/SNI_233_2024","DOI":"10.25259\/SNI_233_2024"},{"key":"9978_CR96","doi-asserted-by":"crossref","unstructured":"Vithalrao Parghane R, Agrawal K, Mittal BR, Shukla J, Bhattacharya A, Mukherjee KK. Ga DOTATATE PET\/CT in a rare coexistence of pituitary Macroadenoma and multiple paragangliomas, 2013. [Online]. Available: www.nuclearmed.com.","DOI":"10.1097\/RLU.0b013e3182a77b78"},{"key":"9978_CR97","doi-asserted-by":"publisher","unstructured":"Lastoria S, et al. Role of 68Ga-DOTATATE PET\/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. Jun. 2016;52(3):488\u201394. https:\/\/doi.org\/10.1007\/s12020-015-0702-y.","DOI":"10.1007\/s12020-015-0702-y"},{"key":"9978_CR98","doi-asserted-by":"publisher","unstructured":"Daya R, Seedat F, Purbhoo K, Bulbulia S, Bayat Z. Acromegaly with empty sella syndrome, Endocrinol Diabetes Metab Case Rep, vol. 2021, no. 1, 2021. https:\/\/doi.org\/10.1530\/EDM-21-0049","DOI":"10.1530\/EDM-21-0049"},{"issue":"3","key":"9978_CR99","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/RLU.0000000000001021","volume":"41","author":"S Basu","year":"2016","unstructured":"Basu S, Ranade R, Hazarika S. 68Ga DOTATATE PET\/CT of synchronous meningioma and prolactinoma. Clin Nucl Med. 2016;41(3):230\u20131. https:\/\/doi.org\/10.1097\/RLU.0000000000001021.","journal-title":"Clin Nucl Med"},{"key":"9978_CR100","doi-asserted-by":"publisher","unstructured":"Novruzov F, et al. The value of [68Ga]Ga-DOTA-TATE PET\/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. Dec. 2021;5(1). https:\/\/doi.org\/10.1186\/s41824-021-00104-3.","DOI":"10.1186\/s41824-021-00104-3"},{"key":"9978_CR101","doi-asserted-by":"publisher","unstructured":"Alexander V, Koshy M, Dasgupta R, Carey RA. Arterial thrombosis as primary presentation of endogenous cushing\u2019s syndrome. BMJ Case Rep. Feb. 2019;12(2). https:\/\/doi.org\/10.1136\/bcr-2018-227491.","DOI":"10.1136\/bcr-2018-227491"},{"key":"9978_CR102","doi-asserted-by":"publisher","unstructured":"Pivonello R, et al. Glucocorticoid receptor antagonism upregulates somatostatin receptor subtype 2 expression in ACTH-Producing neuroendocrine tumors: new insight based on the selective glucocorticoid receptor modulator relacorilant. Front Endocrinol (Lausanne). Jan. 2022;12. https:\/\/doi.org\/10.3389\/fendo.2021.793262.","DOI":"10.3389\/fendo.2021.793262"},{"issue":"4","key":"9978_CR103","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1227\/NEU.0000000000001319","volume":"80","author":"UJ Knappe","year":"2017","unstructured":"Knappe UJ, et al. Ectopic adrenocorticotropic hormone-secreting pituitary adenomas: an underestimated entity. Neurosurgery. 2017;80(4):525\u201333. https:\/\/doi.org\/10.1227\/NEU.0000000000001319.","journal-title":"Neurosurgery"},{"key":"9978_CR104","doi-asserted-by":"publisher","unstructured":"MacFarlane J et al. Novel imaging techniques in refractory pituitary adenomas, Jun. 01, 2023, Springer. https:\/\/doi.org\/10.1007\/s11102-023-01304-9","DOI":"10.1007\/s11102-023-01304-9"},{"key":"9978_CR105","doi-asserted-by":"publisher","unstructured":"Xiao J, Zhu Z, Zhong D, Ma W, Wang R. Improvement in diagnosis of metastatic pituitary carcinoma by 68Ga DOTATATE PET\/CT. Clin Nucl Med. Feb. 2015;40(2):e129\u201331. https:\/\/doi.org\/10.1097\/RLU.0000000000000462.","DOI":"10.1097\/RLU.0000000000000462"},{"key":"9978_CR106","doi-asserted-by":"publisher","unstructured":"Maclean J, Aldridge M, Bomanji J, Short S, Fersht N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation, Pituitary, vol. 17, no. 6, pp. 530\u2013538, Nov. 2014, https:\/\/doi.org\/10.1007\/s11102-013-0540-y","DOI":"10.1007\/s11102-013-0540-y"},{"key":"9978_CR107","doi-asserted-by":"publisher","unstructured":"Rini JN, Keir G, Caravella C, Goenka A, Franceschi AM. Somatostatin receptor PET\/CT\/MRI of head and neck neuroendocrine tumors, American Journal of Neuroradiology, vol. 44, no. 8, pp. 959\u2013966, Aug. 2023, https:\/\/doi.org\/10.3174\/ajnr.A7934","DOI":"10.3174\/ajnr.A7934"},{"key":"9978_CR108","doi-asserted-by":"publisher","unstructured":"Novruzov F, Aliyev JA, Jaunmuktane Z, Bomanji JB, Kayani I. The Use of 68Ga DOTATATE PET\/CT for Diagnostic Assessment and Monitoring of 177Lu DOTATATE Therapy in Pituitary Carcinoma, Clin Nucl Med, vol. 40, no. 1, pp. 47\u201349, Jan. 2015, https:\/\/doi.org\/10.1097\/RLU.0000000000000589","DOI":"10.1097\/RLU.0000000000000589"},{"key":"9978_CR109","doi-asserted-by":"publisher","unstructured":"Walig\u00f3rska-Stachura J, et al. Growth hormone-secreting Macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90 Y-DOTATATE: case report. J Neurosurg. Aug. 2016;125(2):346\u20139. https:\/\/doi.org\/10.3171\/2015.6.JNS15363.","DOI":"10.3171\/2015.6.JNS15363"},{"key":"9978_CR110","doi-asserted-by":"publisher","unstructured":"Boertien TM et al. Jul., Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment, The Lancet Regional Health - Europe, vol. 42, 2024, https:\/\/doi.org\/10.1016\/j.lanepe.2024.100923","DOI":"10.1016\/j.lanepe.2024.100923"},{"key":"9978_CR111","doi-asserted-by":"publisher","unstructured":"Boertien TM, et al. 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. Eur J Hybrid Imaging. Dec. 2020;4(1). https:\/\/doi.org\/10.1186\/s41824-020-0073-3.","DOI":"10.1186\/s41824-020-0073-3"},{"key":"9978_CR112","doi-asserted-by":"publisher","unstructured":"Naswa N, Das CJ, Sharma P, Karunanithi S, Bal C, Kumar R. Ectopic pituitary adenoma with empty sella in the setting of MEN-1 syndrome: Detection with 68Ga-DOTANOC PET\/CT, Jpn J Radiol, vol. 30, no. 9, pp. 783\u2013786, Nov. 2012, https:\/\/doi.org\/10.1007\/s11604-012-0117-0","DOI":"10.1007\/s11604-012-0117-0"},{"key":"9978_CR113","doi-asserted-by":"publisher","unstructured":"Trummer C et al. Feb., Secondary Hyperthyroidism due to an Ectopic Thyrotropin-Secreting Neuroendocrine Pituitary Tumor: A Case Report, Eur Thyroid J, vol. 9, no. 2, pp. 106\u2013112, 2020, https:\/\/doi.org\/10.1159\/000505020","DOI":"10.1159\/000505020"},{"key":"9978_CR114","doi-asserted-by":"publisher","unstructured":"Veit JA, et al. Detection of paranasal ectopic adrenocorticotropic hormone-secreting pituitary adenoma by Ga-68-DOTANOC positron-emission tomography-computed tomography. Laryngoscope. May 2013;123(5):1132\u20135. https:\/\/doi.org\/10.1002\/lary.23867.","DOI":"10.1002\/lary.23867"},{"key":"9978_CR115","doi-asserted-by":"publisher","unstructured":"Karthik S, Krishna T, Johnson JR, Karikkanthra J. Clival ectopic pituitary adenoma causing Cushing syndrome. JCEM Case Rep. Sep. 2023;1(5). https:\/\/doi.org\/10.1210\/jcemcr\/luad115.","DOI":"10.1210\/jcemcr\/luad115"},{"key":"9978_CR116","doi-asserted-by":"publisher","unstructured":"Tj\u00f6rnstrand A et al. Mar., Lower 68Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland\u2014A proof-of-concept study, Clin Endocrinol (Oxf), vol. 92, no. 3, pp. 222\u2013231, 2020, https:\/\/doi.org\/10.1111\/cen.14144","DOI":"10.1111\/cen.14144"},{"key":"9978_CR117","doi-asserted-by":"publisher","unstructured":"Bashir A, Broholm H, Clasen-Linde E, Vestergaard MB, Law I. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging, Clin Nucl Med, vol. 45, no. 6, pp. e279\u2013e280, Jun. 2020, https:\/\/doi.org\/10.1097\/RLU.0000000000003012","DOI":"10.1097\/RLU.0000000000003012"},{"key":"9978_CR118","doi-asserted-by":"publisher","unstructured":"Palmisciano P et al. The Role of [68Ga]Ga-DOTA-SSTR PET Radiotracers in Brain Tumors: A Systematic Review of the Literature and Ongoing Clinical Trials, Jun. 01, 2022, MDPI. https:\/\/doi.org\/10.3390\/cancers14122925","DOI":"10.3390\/cancers14122925"},{"key":"9978_CR119","doi-asserted-by":"publisher","unstructured":"Gauth\u00e9 M, Sarfati J, Bourcigaux N, Christin-Maitre S, Talbot JN, Montravers F. Pituitary adenoma recurrence suspected on central hyperthyroidism despite empty sella and confirmed by 68Ga-DOTA-TOC PET\/CT, Clin Nucl Med, vol. 42, no. 6, pp. 454\u2013455, Mar. 2017, https:\/\/doi.org\/10.1097\/RLU.0000000000001628","DOI":"10.1097\/RLU.0000000000001628"},{"key":"9978_CR120","doi-asserted-by":"crossref","unstructured":"Gani LU, Gianatti EJ, Cheung AS, Jerums G, Macisaac RJ. Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: a case report, 2011. [Online]. Available: http:\/\/www.jmedicalcasereports.com\/content\/5\/1\/405","DOI":"10.1186\/1752-1947-5-405"},{"key":"9978_CR121","doi-asserted-by":"publisher","unstructured":"Wang J, Foley M, Kuker R. Pituitary adenoma on 18F-Fluciclovine PET\/CT. Clin Nucl Med. Jan. 2020;45(1):E65\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000002777.","DOI":"10.1097\/RLU.0000000000002777"},{"key":"9978_CR122","unstructured":"Pirker W et al. And N-methylspiperone for measurement of D2 receptor density in pituitary adenomas."},{"key":"9978_CR123","unstructured":"De Herder WW et al. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D 2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas."},{"key":"9978_CR124","unstructured":"Bergstr\u00f6m MCLPLB. M, PET as a tool in the clinical evaluation of pituitary adenomas, J Nucl Med, Apr. 1991."},{"key":"9978_CR125","doi-asserted-by":"publisher","unstructured":"Colao A, et al. Hormone levels and tumour size response to Quinagolide and Cabergoline in patients with prolactin-secreting and clinically non\u2010functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123 I\u2010methoxybenzamide. Clin Endocrinol (Oxf). Apr. 2000;52(4):437\u201345. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.00951.x.","DOI":"10.1046\/j.1365-2265.2000.00951.x"},{"key":"9978_CR126","doi-asserted-by":"publisher","unstructured":"Zaidi HA, Cote DJ, Laws ER. Current imaging techniques for the diagnosis of pituitary adenoma. Expert Rev Endocrinol Metab. Mar. 2016;11(2):163\u201370. https:\/\/doi.org\/10.1586\/17446651.2016.1151784.","DOI":"10.1586\/17446651.2016.1151784"},{"key":"9978_CR127","doi-asserted-by":"publisher","unstructured":"Damian A et al. Jul., 18F-fallypride and 11\u00a0C-methionine positron emission tomography\/computed tomography for the study of prolactinomas and nonfunctioning pituitary adenomas: A case series, World J Nucl Med, vol. 20, no. 03, pp. 286\u2013293, 2021, https:\/\/doi.org\/10.4103\/wjnm.wjnm_83_20","DOI":"10.4103\/wjnm.wjnm_83_20"},{"key":"9978_CR128","doi-asserted-by":"publisher","unstructured":"Veldhuijzen SEM, van Zanten SJCMM, Neggers R, Valkema, Verburg FA. Positive [18F]fluoroethyltyrosine PET\/MRI in suspected recurrence of growth hormone\u2013producing pituitary adenoma in a paediatric patient, Eur J Nucl Med Mol Imaging, vol. 49, no. 1, pp. 410\u2013411, Dec. 2021, https:\/\/doi.org\/10.1007\/s00259-021-05458-1","DOI":"10.1007\/s00259-021-05458-1"},{"issue":"3","key":"9978_CR129","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2967\/jnmt.113.136291","volume":"42","author":"GM Currie","year":"2014","unstructured":"Currie GM, et al. Pituitary incidentaloma found on O-(2-18F-fluoroethyl)-L-tyrosine PET. J Nucl Med Technol. 2014;42(3):218\u201322. https:\/\/doi.org\/10.2967\/jnmt.113.136291.","journal-title":"J Nucl Med Technol"},{"key":"9978_CR130","doi-asserted-by":"publisher","unstructured":"Bakker LEH et al. Aug., 18F-fluoro\u2010ethyl\u2010tyrosine PET co\u2010registered with MRI in patients with persisting acromegaly, Clin Endocrinol (Oxf), vol. 101, no. 2, pp. 142\u2013152, 2024, https:\/\/doi.org\/10.1111\/cen.15079","DOI":"10.1111\/cen.15079"},{"key":"9978_CR131","doi-asserted-by":"publisher","unstructured":"van Trigt VR, et al. Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants. Pituitary. Oct. 2024;27(5):614\u201324. https:\/\/doi.org\/10.1007\/s11102-024-01430-y.","DOI":"10.1007\/s11102-024-01430-y"},{"key":"9978_CR132","doi-asserted-by":"publisher","unstructured":"Pruis IJ, et al. [18 F]FET PET\/MRI: an accurate technique for detection of small functional pituitary tumors. J Nucl Med. May 2024;65(5):688\u201392. https:\/\/doi.org\/10.2967\/jnumed.123.266853.","DOI":"10.2967\/jnumed.123.266853"},{"key":"9978_CR133","doi-asserted-by":"publisher","unstructured":"A. C. M. Van Den Bergh et al., Tyrosine positron emission tomography and protein synthesis rate in pituitary adenoma: different effects of surgery and radiation therapy. Radiother Oncol, 98, 2, pp. 213\u20136, Feb. 2011, https:\/\/doi.org\/10.1016\/j.radonc.2010.12.020","DOI":"10.1016\/j.radonc.2010.12.020"},{"key":"9978_CR134","doi-asserted-by":"publisher","unstructured":"Wang Z et al. Sep., Utility of 13\u00a0N-Ammonia PET\/CT to Detect Pituitary Tissue in Patients with Pituitary Adenomas, Acad Radiol, vol. 26, no. 9, pp. 1222\u20131228, 2019, https:\/\/doi.org\/10.1016\/j.acra.2018.09.015","DOI":"10.1016\/j.acra.2018.09.015"},{"key":"9978_CR135","doi-asserted-by":"publisher","unstructured":"Maffione AM, Mandoliti G, Pasini F, Colletti PM, Rubello D. Pituitary Non-Functioning adenoma disclosed at 18F-Choline PET\/CT to investigate a prostate Cancer relapse. Clin Nucl Med. Oct. 2016;41(10):e460\u20131. https:\/\/doi.org\/10.1097\/RLU.0000000000001328.","DOI":"10.1097\/RLU.0000000000001328"},{"key":"9978_CR136","doi-asserted-by":"publisher","unstructured":"Walia R et al. MOLECULAR IMAGING TARGETING CORTICOTROPIN RELEASING HORMONE RECEPTOR FOR CORTICOTROPINOMA: A CHANGING PARADIGM, https:\/\/doi.org\/10.1210\/clinem\/dgaa755\/5932348","DOI":"10.1210\/clinem\/dgaa755\/5932348"},{"key":"9978_CR137","doi-asserted-by":"publisher","unstructured":"Ginet M, Cuny T, Schmitt E, Marie PY, Verger A. 18F-FDOPA PET Imaging in Prolactinoma, Clin Nucl Med, vol. 42, no. 8, pp. e383\u2013e384, Aug. 2017, https:\/\/doi.org\/10.1097\/RLU.0000000000001721","DOI":"10.1097\/RLU.0000000000001721"},{"key":"9978_CR138","doi-asserted-by":"publisher","unstructured":"More J, et al. Ectopic ACTH syndrome in children and adolescents. J Clin Endocrinol Metab. May 2011;96(5):1213\u201322. https:\/\/doi.org\/10.1210\/jc.2010-2276.","DOI":"10.1210\/jc.2010-2276"},{"key":"9978_CR139","doi-asserted-by":"publisher","unstructured":"Hodolic M et al. Sep., Incidental uptake of 18F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer, Radiol Oncol, vol. 48, no. 3, pp. 228\u2013234, 2014, https:\/\/doi.org\/10.2478\/raon-2013-0075","DOI":"10.2478\/raon-2013-0075"},{"key":"9978_CR140","doi-asserted-by":"publisher","unstructured":"Sindoni A, Bodanza V, Tatta R, Baresic T, Borsatti E. Ectopic adrenocorticotropic Hormone\u2013Secreting pituitary adenoma localized by 18F-Choline PET\/CT. Clin Nucl Med. Jan. 2018;43(1):E25\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000001889.","DOI":"10.1097\/RLU.0000000000001889"},{"key":"9978_CR141","doi-asserted-by":"publisher","unstructured":"Tj\u00f6rnstrand A, Nystr\u00f6m HF, DIAGNOSIS OF ENDOCRINE DISEASE. Diagnostic approach to TSH-producing pituitary adenoma. Eur J Endocrinol. Oct. 2017;177(4):R183\u201397. https:\/\/doi.org\/10.1530\/EJE-16-1029.","DOI":"10.1530\/EJE-16-1029"},{"key":"9978_CR142","doi-asserted-by":"publisher","unstructured":"Gillett D et al. Dec., Methods of 3D printing models of pituitary tumors, 3D Print Med, vol. 7, no. 1, 2021, https:\/\/doi.org\/10.1186\/s41205-021-00118-4","DOI":"10.1186\/s41205-021-00118-4"},{"key":"9978_CR143","doi-asserted-by":"publisher","unstructured":"Buchfelder M, Schlaffer S-M. Modern imaging of pituitary adenomas. Front Horm Res. 2010;109\u201320. https:\/\/doi.org\/10.1159\/000318500.","DOI":"10.1159\/000318500"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-09978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-025-09978-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-09978-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:03:29Z","timestamp":1762877009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-025-09978-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9978"],"URL":"https:\/\/doi.org\/10.1007\/s11154-025-09978-1","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"3 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}